Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3400+0.0600 (+1.83%)
At close: 04:00PM EST
3.4900 +0.15 (+4.49%)
After hours: 06:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 757.95M
Enterprise value 174.45M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)19.05
Price/book (mrq)0.92
Enterprise value/revenue 4.46
Enterprise value/EBITDA -0.86

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-42.25%
S&P500 52-week change 3-10.08%
52-week high 38.7400
52-week low 32.7400
50-day moving average 33.5621
200-day moving average 35.4253

Share statistics

Avg vol (3-month) 31.19M
Avg vol (10-day) 31.11M
Shares outstanding 5249.33M
Implied shares outstanding 6N/A
Float 8147.65M
% held by insiders 115.74%
% held by institutions 166.10%
Shares short (12 Jan 2023) 417.96M
Short ratio (12 Jan 2023) 412.92
Short % of float (12 Jan 2023) 410.33%
Short % of shares outstanding (12 Jan 2023) 47.20%
Shares short (prior month 14 Dec 2022) 417.11M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-559.17%

Management effectiveness

Return on assets (ttm)-12.57%
Return on equity (ttm)-28.61%

Income statement

Revenue (ttm)39.12M
Revenue per share (ttm)0.16
Quarterly revenue growth (yoy)-99.90%
Gross profit (ttm)10.65M
EBITDA -201.2M
Net income avi to common (ttm)-258.43M
Diluted EPS (ttm)1.4700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)648.13M
Total cash per share (mrq)2.6
Total debt (mrq)67.47M
Total debt/equity (mrq)8.23
Current ratio (mrq)12.88
Book value per share (mrq)3.29

Cash flow statement

Operating cash flow (ttm)-162.5M
Levered free cash flow (ttm)-73.14M